Korea pharma 2027 — biosimilars go global, the CDMO capacity build compounds
South Korea's pharma story in 2027 sits in exports, not the home market. Medicine exports reached USD 10.4 bn in 2025, up 11.8%, with biologics at 62.6% of the total [KPBMA 2026]. Two biosimilar developers led the world with 5 of 18 US FDA approvals in 2025 [MDToday 2026], while Songdo's contract bioreactor base — 785k L at Samsung Biologics alone [SBL FY25] — fills with patent-cliff, GLP-1 and BIOSECURE-driven demand toward 2030.
Executive summary
South Korea's pharmaceutical market is valued at approximately $26 billion in 2025, supported by National Health Insurance (NHI) universal coverage. The domestic industry has historically been dominated by generic manufacturers, but a strategic national investment in biopharmaceuticals has produced genuine global capabilities: Samsung Biologics is the world's largest biopharmaceutical contract manufacturer by capacity, and Celltrion launched the world's first biosimilar infliximab. Korean biopharmaceutical companies are increasingly competitive in the global biosimilar market, generating significant export revenue to the US and Europe. Domestic R&D investment has grown to 6.2% of industry revenue, supporting new drug pipeline development particularly in oncology and autoimmune therapeutics. This report covers Korea's pharmaceutical market by segment, NHI reimbursement dynamics, biosimilar industry development, Samsung Biologics CDMO strategy, domestic generic landscape, and the export outlook through 2027.
Report details
- Published
- 2026-06-02
- Pages
- 15
- Format
- Code
- KR-PHA-XPL-D27-01
- Market
- South Korea
- Industry
- Pharma
- Year
- 2026
Table of contents · 12 sections
- 04 Executive summary
- 05 Strategic implications
- 06 Demand & the export engine
- 07 Market size & the export mix
- 08 Korea's global biosimilar position
- 09 CDMO capacity build
- 10 The Songdo capacity race
- 11 What fills the new capacity
- 12 Biosimilar global expansion
- 13 Six patent-cliff windows
- 14 Regulatory & policy ladder
- 15 2025-2030 forecast & sources
The full report is available to subscribers and buyers. The executive summary above is free to read.